Soluble Urokinase Plasminogen Activator Receptor and Venous Thromboembolism in COVID‐19 [PDF]
Background Venous thromboembolism (VTE) contributes significantly to COVID‐19 morbidity and mortality. The urokinase receptor system is involved in the regulation of coagulation.
Shengyuan Luo +29 more
doaj +6 more sources
Soluble urokinase plasminogen activator receptor – What are the clinical potentials in psychiatry? [PDF]
Background: Mental disorders have been associated with systemic chronic inflammation, and conditions such as depression and schizophrenia are increasingly linked to inflammatory processes.
Franziska Grundtvig Huber +4 more
doaj +4 more sources
Soluble Urokinase Plasminogen Activator Receptor Measurements: Influence of Sample Handling [PDF]
Aim The influence of sample handling on soluble urokinase plasminogen activator receptor (suPAR) concentrations in serum and EDTA plasma was studied in 16 healthy premenopausal women.
R. Riisbro +4 more
doaj +4 more sources
Soluble urokinase plasminogen activator receptor and perioperative complications: a systematic review [PDF]
Background Better informative predictive tools are required to improve risk-stratification in patients undergoing surgery. Soluble urokinase-type plasminogen activator receptor (suPAR) has the potential to predict postoperative complications. The primary
Ata B. Gungor +4 more
doaj +5 more sources
Soluble urokinase plasminogen activator receptor is a prognostic biomarker in decompensated cirrhosis [PDF]
Background & Aims: Cirrhosis poses a significant healthcare burden, with decompensation and acute-on-chronic liver failure (ACLF) resulting in high morbidity and mortality. Reliable biomarkers of disease progression are urgently needed.
Sven Lamatsch +25 more
doaj +5 more sources
Soluble urokinase plasminogen activator receptor and cardiotoxicity in doxorubicin-treated breast cancer patients: a prospective exploratory study [PDF]
Background Soluble urokinase plasminogen activator receptor is an inflammatory biomarker that may prognosticate cardiovascular outcomes. We sought to determine the associations between soluble urokinase plasminogen activator receptor and established ...
Jian Chu +10 more
doaj +3 more sources
Soluble urokinase plasminogen activator receptor and outcomes in HFpEF: A TOPCAT ancillary study [PDF]
Aims Inflammation is postulated to be a key pathogenic mechanism in heart failure with preserved ejection fraction (HFpEF). Soluble urokinase plasminogen activator receptor (suPAR), a regulator of innate immune activity, is associated with incident heart
Christina G. Hutten +9 more
doaj +4 more sources
Proteomics-Based Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated With Incident Heart Failure Risk [PDF]
Background: Higher soluble urokinase plasminogen activator receptor (suPAR) levels are associated with adverse outcomes in chronic heart failure (HF). Objectives: The authors assessed the association between proteomics-based suPAR levels and incident HF ...
Adithya K. Yadalam, MD, MSc +11 more
doaj +4 more sources
Background: The objective of this study is to indicate the role of urokinase plasminogen activator receptor (uPAR), soluble uPAR (suPAR), and β1 integrin in tumor growth and invasion of lymph nodes from Hodgkin's lymphoma (HL) patients.
Shirin Kouhpayeh +5 more
doaj +3 more sources
Soluble Urokinase Plasminogen Activator Receptor [PDF]
Background and Purpose— Recent studies indicate that the urokinase system could have an important role in atherogenesis and plaque rupture. The relationships among the soluble urokinase plasminogen activator receptor (suPAR), carotid plaque, and incidence of ischemic stroke and coronary artery disease (CAD) events were studied ...
Margaretha, Persson +6 more
core +4 more sources

